Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ High Yield Corporate Bond ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $76.76 (market cap $17.41B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: iShares iBoxx $ High Yield Corporate Bond ETF is far larger — about 2.4× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ High Yield Corporate Bond ETF for 61 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| HYG | SYRE | |
|---|---|---|
Market Cap | $17.41B | $7.35B |
Volume | 63,579,674 | 1,624,631 |
Sector | Fixed Income | Health |
52-Week High | $81.28 | $108.92 |
52-Week Low | $76.81 | $22.18 |
Typical Hold Time | 61 Days | 0 Days |
Enterprise Value | — | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HYG trades at $77.09, down 0.26% amid a bearish technical signal with moving averages indicating selling pressure. The ETF shows neutral oscillator readings with mixed RSI signals. Recent corporate actions include dividend payments scheduled for 2026. The broader bond market faces pressure from rising Treasury yields, with the 10-year yield hitting levels not seen since 2007 according to MarketBeat on September 30, 2026.
The outlook remains cautious as high yield corporate bonds face headwinds from rising interest rates and inflationary pressures. Investment opportunities exist for income-focused investors through scheduled dividends, but risks include continued bond market volatility and economic uncertainty. HYG's performance will be closely tied to Federal Reserve policy and corporate credit conditions.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
